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Introduction: SARS-CoV-2, a novel coronavirus, manifests as a respiratory syndrome (COVID-19) 
and is the cause of an ongoing pandemic. The response to COVID-19 in the United States has been 
hampered by an overall lack of diagnostic testing capacity. To address uncertainty about ongoing 
levels of SARS-CoV-2 community transmission early in the pandemic, we aimed to develop a 
surveillance tool using readily available emergency department (ED) operations data extracted from 
the electronic health record (EHR). This involved optimizing the identification of acute respiratory 
infection (ARI)-related encounters and then comparing metrics for these encounters before and after 
the confirmation of SARS-CoV-2 community transmission.  
Methods: We performed an observational study using operational EHR data from two Midwest EDs 
with a combined annual census of over 80,000. Data were collected three weeks before and after 
the first confirmed case of local SARS-CoV-2 community transmission. To optimize capture of ARI 
cases, we compared various metrics including chief complaint, discharge diagnoses, and ARI-related 
orders. Operational metrics for ARI cases, including volume, pathogen identification, and illness 
severity, were compared between the pre- and post-community transmission timeframes using chi-
square tests of independence.  
Results: Compared to our combined definition of ARI, chief complaint, discharge diagnoses, and 
isolation orders individually identified less than half of the cases. Respiratory pathogen testing was 
the top performing individual ARI definition but still only identified 72.2% of cases. From the pre to 
post periods, we observed significant increases in ED volumes due to ARI and ARI cases without 
identified pathogen. 
Conclusion: Certain methods for identifying ARI cases in the ED may be inadequate and multiple 
criteria should be used to optimize capture. In the absence of widely available SARS-CoV-2 
testing, operational metrics for ARI-related encounters, especially the proportion of cases involving 
negative pathogen testing, are useful indicators for active surveillance of potential COVID-19 
related ED visits. [West J Emerg Med. 2020;21(4)X–X.]
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Disclaimer: Due to the rapidly evolving nature of this outbreak, 
and in the interests of rapid dissemination of reliable, actionable 
information, this paper went through expedited peer review. 
Additionally, information should be considered current only at the 
time of publication and may evolve as the science develops. 
INTRODUCTION
SARS-CoV-2, a novel coronavirus, is the cause of an 
ongoing global pandemic. It can cause a serious respiratory 
illness, termed COVID-19, with comorbid and older adults 
at increased risk of death.1,2 While other affected countries 
instituted widespread testing for SARS-CoV-2 as part of 
early and successful mitigation efforts, due to a variety of 
factors, diagnostic testing efforts in the United States (US) 
during early phases of community spread continue to be 
significantly hampered.3,4 The lack of testing capacity resulted 
in stringent testing recommendations from the Centers for 
Diseases Control and Prevention, which specifically excluded 
asymptomatic or mildly symptomatic individuals. The delay 
in community-based surveillance has generated substantial 
uncertainty among health systems attempting to prepare 
for a surge in cases and severely limited a primary tool of 
pandemic mitigation: source identification and contract 
tracing. Early detection of a surge in emergency department 
(ED) COVID-19 cases is essential to guide response plans if 
hospitals hope to avoid overwhelmed systems. 
Therefore, faced with the absence of a readily available 
rapid diagnostic assay, we developed a simple, electronic 
health record (EHR)-based tracking tool to detect variations 
in encounters due to acute respiratory infections (ARI), 
organism identification for ARIs, or ARI acuity related to 
potential unrecognized COVID-19 community transmission. 
The first step was to develop a process for identifying ARI 
using available EHR data. The second step was to determine 
whether we could detect a significant change in ARI case 
without identified pathogen as a metric of potential COVID-19 
community transmission.
METHODS
We conducted this project using combined EHR data 
from an academic medical center ED with over 60,000 patient 
visits per year and an affiliated community ED with over 
20,000 annual visits. Data were collected for ED arrivals from 
February 17-March 30, 2020, which included three weeks 
before and after confirmed local SARS-CoV-2 transmission. 
All ED visits during this time period were included in our 
dataset and examined for potential ARI. SARS-CoV-2 testing 
was available via the state department of health and later in-
house during the post three-week time period but for select 
patient groups only.5 All data were electronically extracted 
from the EHR by an experienced data analyst. This project 
was considered quality improvement and did not meet the 
federal definition of human subject research pursuant to 45 
CFR 46 as assessed using a self-certification tool provided by 
our institutional health sciences institutional review board.
Using the consensus of our departmental COVID-19 
response team, including ED operations, informatics, and 
infectious diseases experts, we identified four potential 
EHR-based criteria to identify ARI encounters and a series 
of operational metrics for inclusion in an ARI outbreak 
tracking tool. Each selected metric needed to satisfy two basic 
criteria: 1) readily extractable electronically from existing 
EHR data; 2) involve only simple calculations for ease of 
interpretation and translation to other EHR platforms. For the 
first metric, overall ARI volume, we applied four criteria to 
all ED encounters to determine what would provide the most 
comprehensive capture of potential cases: 1) chief complaints 
specific to ARI (cough, flu-like symptoms, sore throat, 
upper respiratory symptoms, sinus symptoms); 2) discharge 
diagnoses specific to ARI (ICD-10 codes J00-J06, J09-J18, 
J20-J22, J40); 3) respiratory pathogen isolation order; and 4) 
respiratory pathogen test order (influenza/respiratory syncytial 
virus assay, group A streptococcus swab, expanded viral 
polymerase chain reaction [PCR] panel). 
Given the disproportionate rate of critical illness among 
patients with COVID-19 as compared to other ARI (e.g., 
seasonal influenza), we then included three metrics of severity: 
1) percentage of patients with ARI requiring admission; 2) 
percentage of patients with ARI admitted to intermediate 
care or intensive care units (IMC/ICU); and 3) percentage 
of patients with ARI receiving antibacterial therapy. The 
antibiotic metric was included to capture any increase in ARI 
patients being treated with empiric antibiotics (e.g., met sepsis 
criteria). Finally, given the restricted testing criteria in place 
and ongoing uncertainty about the SARS-CoV-2 RNA PCR 
assay’s sensitivity and specificity6 to identify ARI encounters, 
potentially due to undiagnosed COVID-19, we selected a 
metric of percent ARI without an identified pathogen on any 
organism identification assay. This was selected due to the 
lack of discriminating clinical features between influenza 
and COVID-19 and the ongoing routine use of influenza/
respiratory syncytial virus (RSV), expanded viral panel and 
group A strep assays for ARIs in our ED. Data were extracted 
from the EHR and analyzed using R 3.6.2 (The R Project for 
Statistical Computing, CRAN). We compared proportions of 
encounters before and after community transmission using a 
chi-square test.
RESULTS
The combined overall ED census in our two departments 
decreased from 5213 to 3550 (-1663 encounters) from the pre- 
to post-time period, but the proportion of ED visits due to ARI 
increased significantly (6.6%, 95% confidence interval 4.6-
8.5%, p<.001). When identifying ARI cases, we first created 
a combination definition using the union of all four individual 
criteria and applied it to all ED encounters. This identified 
2540 total ARI encounters over the six-week period. When 
examined individually, each of the four criteria identified 
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preserve personal protective equipment (PPE) or testing 
capacity. Despite rapid progress in available diagnostics, 
ongoing concerns over PPE and reagent shortages will 
continue to hamper widespread community surveillance 
testing in the US.7  
Our approach expands upon more basic methods for ED-
based seasonal influenza surveillance efforts by evaluating 
a multi-component definition of ARI that combines chief 
complaints and discharge diagnoses with actual orders for 
respiratory isolation and pathogen testing. Our results suggest 
the traditional approach of using chief complaint (e.g., 
influenza-like illness [ILI]) and/or discharge diagnoses alone 
may be inadequate for comprehensive identification of ARI 
encounters.8 Of note, we did exclude fever alone in our chief 
complaint definition as it is not specific to ARI and would 
result in capture of many infections unrelated to COVID-19 
(e.g., urinary tract and skin infections). 
In the case of a respiratory pandemic due to a novel 
pathogen, traditional, laboratory-based surveillance will also 
be ineffective. Based on ongoing influenza activity during 
the study time period and its similar clinical presentation to 
COVID-19, we selected percentage of ARI cases receiving 
pathogen testing with negative results as our metric for 
potential cases of undiagnosed COVID-19. The observed 
significant increase in overall ARI encounters and those without 
identified pathogen mirrors national observations of increased 
encounters for ILI without identified pathogen over the same 
time periods.9-11 This late-season spike in ILI cases, which did 
not occur in previous years, was confirmed in one report from 
Los Angeles to partially represent community transmission 
of COVID-19. Among patients with ILI who were tested for 
SARS-CoV-2, they observed a 5% positivity rate which is 
similar to our findings (6% positivity), suggesting a similar 
community transmission burden in disparate geographic 
locations around the same time period.11 Although we did not 
demonstrate a difference in our markers of ARI severity, we 
attribute this to continued low volumes of COVID-19 cases 
in our community. We anticipate these metrics will become 
increasingly valuable for early identification of a need for 
additional intensive care resources should ongoing mitigation 
efforts not succeed in flattening the outbreak curve locally.
LIMITATIONS
For ARI case identification, it is possible that cases 
that would have been identified with manual chart review 
were excluded. Given the dynamic nature of the ongoing 
COVID-19 pandemic and limited post-community spread 
data available for analysis, we did not perform a formal, 
interrupted time series analysis to account for temporal effects. 
ARI volumes and percentage of ARI cases without identified 
pathogen must be interpreted based on local outbreak 
dynamics. As population-level surveillance metrics, these 
indicators should not be used to inform diagnosis or treatment 
decisions for individual patients. 
Figure. Number of acute respiratory infection encounters identi-
fied by different criteria.
ARI, acute respiratory infections; ED, emergency department.
unique ARI cases (Figure). Specifically, when compared to the 
combined definition, chief complaint specific to ARI identified 
32.7% of cases while discharge diagnosis related to ARI 
identified 42.4% of cases. Orders for respiratory pathogen 
isolation or respiratory pathogen testing identified 33.7% and 
72.2% of cases, respectively. 
The Table compares our selected ED ARI metrics from three 
weeks before and three weeks after the local onset of community 
SARS-CoV-2 transmission. ARI encounters without an identified 
pathogen increased despite no change in the proportion of ARI 
encounters receiving pathogen testing. Of note, only 40% of 
ARI encounters received SARS-CoV-2 testing in the post period 
with a positivity rate of 6% (27/462 tested). In terms of acuity 
metrics, we did not detect a statistically significant change in 
overall ARI admissions or those requiring IMC/ICU care. There 
was a statistically significant decline in the proportion of ARI 
cases receiving antibiotics.  
DISCUSSION
In the early stages of the COVID-19 pandemic, we 
developed an ED surveillance tool for ARI encounters 
potentially related to undiagnosed community transmitted 
SARS-CoV-2 using readily available EHR data and simple 
calculations. As such, this tool could be easily implemented 
at other institutions. This approach to surveillance would 
especially benefit hospitals that do not currently have access 
to rapid SARS-CoV-2 identification assays or those adhering 
to restricted COVID-19 testing criteria as part of efforts to 
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Pre-Community 
Transmission (n = 1372)
Post-Community 
Transmission (n = 1168)
Difference in Proportions
(%, 95% CI) P value
Pathogen Testing 998 (72.7% ) 835 (71.5% ) -1.2% (-4.8%,2.2%) 0.512
Negative Pathogen Test 578 (42.1%) 642 (55.0%) 12.9% (9%,16.7%) <0.001
Admitted 412 (30.0%) 374 (32.0%) 2% (-1.6%,5.6%) 0.299
Admitted to IMC/ICU 79 (5.8%) 83 (7.1%) 1.3% (-0.6%,3.3%) 0.192
Antibiotic Use 245 (17.9%) 165 (14.1%) -3.8% (-6.6%,-0.9%) 0.001
CI, confidence interval; IMC, intermediate care unit; ICU, intensive care unit.
Table. Acute respiratory infection-related emergency department encounter metrics before and after community transmission of SARS-CoV-2.
CONCLUSION
In this project, we evaluated a strategy for using EHR 
data to identify ARI-related ED encounters and demonstrated 
significant changes in metrics related to these encounters 
during the onset of local community SARS-CoV-2 
transmission. ARI without identified pathogen encounters may 
serve as a lead population-level surveillance indicator for ARI 
outbreaks related to novel pathogens, such as the ongoing 
COVID-19 pandemic.
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